Student Affairs*

“Cancer mechanism discovery and medically translation” is our goal to establish this Institution as research orient education Institute. Four education purposes were setup as “Germination”, “Inspiration”, “Communication” and “Benevolence”. The special education focus on the “Cancer Molecular Medicine” has  made us developed a strong interaction with clinic in order to understand and linked as team for future translation from basic research bench to the bed side. The strong courses involved basic knowledge education of molecular cell biology and cancer biology with selectively design of special lectures to linked our research interested to internationally. In addition, we invited clinicians and businessmen to give lectures to our students in order to capture the frontline of research and business development. These courses help our students understand what will be the best choice after their graduation. We hope by these strong and well developed course design, student will have multi-selection not only on research but also business as freedom of their future selection.



The Graduate Institute of Cancer Biology (GICB) was founded in August 2007 as part of China Medical University. GICB is the only graduate institute with a specific focus on cancer biology in Taiwan, revealing its unique position in offering a strong training environment in cancer biology. This targeted focus provides a good foundation for students interested in the field of oncology, or scientists pursuing cancer research. GICB also represents our institutional commitments: Germination, Inspiration, Communication and Benevolence.


Currently GICB has 8 full time faculty member from internationally. The faculties are integrally involved in the educational mission of the university and the maintenance of an active research program. Each member is and will be recognized for their individual and collaborative pursuits.


GICB Master’s Degree Program introduces students to knowledge derived from research in the formation, properties, and therapy of cancer and assures that students have the necessary background and techniques to enable them to do original research. It is enhanced by close interaction with graduate institutes of Basic Medical Science, Clinic Medical Science and Molecular Systems Biomedicine, and the Department of Medicine.

As a part of CMU, GICB will actively participate in a joint “Cancer Biology and Drug Development” Ph.D. program (estimated enrolling date: September 2008) between CMU and Academia Sinica, the highest academic institution in Taiwan.
In addition, CMU and GSBS at UTHSC/MDACC are currently discussing potential collaborations to have a joint Ph.D. program.


Major courses offered by GICB are:

  • Advance Molecular Cell Biology
  • Cancer Biology
  • Translational Medicine
  • Seminar Series
  • Special Lectures of Biomedical Science
  • Specific Topics in Cancer Gene Therapy
  • Specific Topics in Tumor Microenvironment
  • Specific Topics in Cancer Signaling Pathways
  • Specific Topics in Tumor Biology
  • Specific Topics in Oncoprotein Post-Translational Modification
  • Specific Topics in Cancer Epigenetics

In addition, the students in GICB are encouraged to choose courses from the Medical School. They are also eligible to take clinic-related courses from the Graduate Institute of Clinical Medical Science to enhance their knowledge in the field of clinical research.


The lab space of GICB is fully equipped and is used primarily for cell biomedical and molecular biological studies. In addition, there are several state-of-the art equipment used in the field of proteomic, genomic or molecular imaging which are shared by GICB and the Center for Molecular Medicine (CMM) at China Medical University Hospital.

Research Focus

GICB has a collaborative research partnership with CMM. Recent faculty recruitment has substantially increased our research activities. The rate of PI’s grant funding is 100% with a multi-year commitment of support by the federal agency. The majority of the research in the GICB focuses directly on human cancer and has shown major gains in breast cancer, lung cancer, prostate cancer, and translational research.